Free shipping on all orders over $ 500

SKLB1002

Cat. No. M3013

All AbMole products are for research use only, cannot be used for human consumption.

SKLB1002 Structure
Size Price Availability Quantity
10mg USD 140  USD140 In stock
50mg USD 440  USD440 In stock
100mg USD 680  USD680 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.

Protocol (for reference only)
Cell Experiment
Cell lines HUVECs, L-02, B16-F10, HepG2, and SW620 cells.
Preparation method Cell proliferation Using MTT assay to measure cell proliferation . Various cells including HUVECs, L-02, B16-F10, HepG2, and SW620 are treated with indicated concentrations of SKLB1002 for 24 hours. Vandetanib and sunitinib serve as positive controls. Each assay is replicated 3 times.
Concentrations ~40 μM
Incubation time 24 hours
Animal Experiment
Animal models Mice bearing SW620 or HepG2 tumors
Formulation 35% (v/v) polyethylene glycol solution containing 5% (v/v) DMSO
Dosages ~100 mg/kg daily
Administration i.p.
Chemical Information
Molecular Weight 320.39
Formula C13H12N4O2S2
CAS Number 1225451-84-2
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Qiu-Yang Zhang, et al. SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo

[2] Heng-Xiu Yan, et al. A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis

[3] Wen Nie, et al. Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26

[4] G Shen, et al. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy

[5] Shuang Zhang, et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo

Related VEGFR/PDGFR Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.
SU5208 

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
VEGFR-IN-1 

VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.
(Z)-Orantinib

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively.
(Rac)-SAR131675 

(Rac)-SAR131675 is the racemate of SAR131675.
  Catalog
Abmole Inhibitor Catalog




Keywords: SKLB1002 supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.